Aratana Therapeutics Inc., a Leawood-based company that focuses on treatments for pets, has received federal approval of its third product in five months.
The company said Monday that the Federal Drug Administration’s Center for Veterinary Medicine had granted approval of a long-lasting, local anesthetic for cranial cruciate ligament surgery in dogs. Aratana said it expects the product, called Nocita, will be commercially available to veterinarians this fall.
“As our third FDA-approved therapeutic this year, we are pivoting our attention to successfully bringing these (products) to market over the coming months,” Steven St. Peter, Aratana’s president and chief executive said in the announcement.
The company, which is publicly traded on the Nasdaq Stock Market, recently reported second-quarter net income of $21.2 million, compared with a net loss of $8 million in the same quarter last year. Revenue reached $38 million in the three months that ended June 30. The six-year-old company is based at 11400 Tomahawk Creek Parkway.